Investment analysts at Barclays Capital boosted their price objective on shares of Mylan (NASDAQ:MYL) from $33.00 to $50.00 in a note issued to investors on Tuesday, AnalystRatings.Net reports. The firm currently has an “overweight” rating on the stock. Barclays Capital’s target price suggests a potential upside of 35.80% from the stock’s previous close.
Mylan (NASDAQ:MYL) opened at 36.82 on Tuesday. Mylan has a 52-week low of $23.04 and a 52-week high of $37.10. The stock’s 50-day moving average is currently $32.15. The company has a market cap of $14.036 billion and a price-to-earnings ratio of 22.59.
MYL has been the subject of a number of other recent research reports. Analysts at Morgan Stanley upgraded shares of Mylan to an “overweight” rating in a research note to investors on Monday. Separately, analysts at Guggenheim raised their price target on shares of Mylan from $30.00 to $35.00 in a research note to investors on Monday. They now have a “neutral” rating on the stock. Finally, analysts at Cowen and Company upgraded shares of Mylan from a “market perform” rating to an “outperform” rating in a research note to investors on Monday. They now have a $45.00 price target on the stock, up previously from $29.00.
One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company. Mylan currently has a consensus rating of “Buy” and an average target price of $37.15.
Mylan, Inc develops and markets generics along with a number of proprietary drugs. The Company’s product is for the treatment of migraine headaches, an orphan drug for the on/off fluctuation in people with Parkinson’s disease, and a wound care product to treat diabetic foot ulcers.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.